☆ 4.0 Article

Identification of a possible proteomic biomarker in Parkinson's disease: discovery and replication in blood, brain and cerebrospinal fluid

BRAIN COMMUNICATIONS (2022)

Related references

Note: Only part of the references are listed.

Review Radiology, Nuclear Medicine & Medical Imaging

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers

N. J. Ashton et al.

Summary: The development of blood biomarkers for Alzheimer's disease has shown promise for dementia diagnosis and early detection. Plasma p-tau has demonstrated analytical and clinical validity, while A beta's maturity level remains partially achieved. Despite progress in phases 1 through 3, more data is needed on covariate effects on biomarker measurement.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

Add to Collection

Review Medicine, General & Internal

Alzheimer's disease

Philip Scheltens et al.

Summary: Alzheimer's disease is projected to see a significant increase in prevalence in the future, with genetics playing a key role. Novel biomarkers and lifestyle-based prevention trials show promising therapeutic potential. Promising pharmacological treatments are advancing in clinical trials, targeting amyloid beta, tau, and inflammation.

LANCET (2021)

Add to Collection

Review Neurosciences

Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics

Henrik Zetterberg et al.

Summary: Four fluid-based biomarkers have been developed as diagnostic tests for AD pathology, including markers for plaque pathology, AD-related changes in tau metabolism, and neurodegeneration. These biomarkers can be measured in cerebrospinal fluid or blood samples, aiding in the diagnosis of mild cognitive impairment or dementia due to AD.

MOLECULAR NEURODEGENERATION (2021)

Add to Collection

Review Medicine, General & Internal

Parkinson's disease

Bastiaan R. Bloem et al.

Summary: Parkinson's disease is a neurodegenerative condition with diverse causes and clinical presentations. Diagnosis is clinically based, and treatment goals vary from person to person, emphasizing the need for personalized management. Currently, there is no therapy to slow down or arrest the progression of Parkinson's disease.

LANCET (2021)

Add to Collection

Letter Clinical Neurology

Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population-Based 10-Year Study

Kathrin Marini et al.

MOVEMENT DISORDERS (2021)

Add to Collection

Article Clinical Neurology

Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders

Isabel Schulz et al.

Summary: Objective diagnostic biomarkers are needed to support a clinical diagnosis of neurodegenerative disorders, with various markers being analyzed in serum and/or cerebrospinal fluid for alpha-synuclein-related disorders. Levels of most markers tested significantly differed between disease groups and healthy controls, with CSF NfL levels best discriminating between Parkinson's disease and multiple system atrophy.

MOVEMENT DISORDERS (2021)

Add to Collection

Article Health Care Sciences & Services

Influence of individual, illness and environmental factors on place of death among people with neurodegenerative diseases: a retrospective, observational, comparative cohort study

Richard Nicholas et al.

Summary: This study found that people with multiple sclerosis are more likely to die in hospital, while those with Parkinson's disease are more likely to die outside of hospital settings. Examining individual clinical encounters showed increased contact with services in the 12 months before death, but was not associated with non-hospital deaths. Advance care planning and recognition of dying were found to be high among people with MS and PD, and were associated with non-hospital deaths.

BMJ SUPPORTIVE & PALLIATIVE CARE (2021)

Add to Collection

Article Clinical Neurology

Blood biomarkers with Parkinson's disease clusters and prognosis: the oxford discovery cohort

Michael Lawton et al.

MOVEMENT DISORDERS (2020)

Add to Collection

Review Neurosciences

An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead

Joel Simren et al.

CURRENT OPINION IN NEUROBIOLOGY (2020)

Add to Collection

Article Clinical Neurology

Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression

Brit Mollenhauer et al.

MOVEMENT DISORDERS (2020)

Add to Collection

Review Immunology

The good, the bad, and the opportunities of the complement system in neurodegenerative disease

Nicole D. Schartz et al.

JOURNAL OF NEUROINFLAMMATION (2020)

Add to Collection

Review Clinical Neurology

CSF and blood biomarkers for Parkinson's disease

Lucilla Parnetti et al.

LANCET NEUROLOGY (2019)

Add to Collection

Article Clinical Neurology

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

Liu Shi et al.

ALZHEIMERS & DEMENTIA (2019)

Add to Collection

Article Medicine, General & Internal

Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis

Marijan Posavi et al.

PLOS MEDICINE (2019)

Add to Collection

Review Immunology

Complement in the pathogenesis of Alzheimer's disease

B. Paul Morgan

SEMINARS IN IMMUNOPATHOLOGY (2018)

Add to Collection

Article Biochemistry & Molecular Biology

A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease

Nicholas T. Seyfried et al.

CELL SYSTEMS (2017)

Add to Collection

Article Genetics & Heredity

The Parkinson's Disease-Associated Protein Kinase LRRK2 Modulates Notch Signaling through the Endosomal Pathway

Yuzuru Imai et al.

PLOS GENETICS (2015)

Add to Collection

Review Clinical Neurology

The Prevalence of Parkinson's Disease: A Systematic Review and Meta-analysis

Tamara Pringsheim et al.

MOVEMENT DISORDERS (2014)

Add to Collection

Article Clinical Neurology

The influence of age and gender on motor and non-motor features of early Parkinson's disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort

Konrad Szewczyk-Krolikowski et al.

PARKINSONISM & RELATED DISORDERS (2014)

Add to Collection

Article Clinical Neurology

Plasma Apolipoprotein A1 as a Biomarker for Parkinson Disease

Judy K. Qiang et al.

ANNALS OF NEUROLOGY (2013)

Add to Collection

Review Neurosciences

Axon degeneration in Parkinson's disease

Robert E. Burke et al.

EXPERIMENTAL NEUROLOGY (2013)

Add to Collection

Article Biotechnology & Applied Microbiology

clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters

Guangchuang Yu et al.

OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)

Add to Collection

Article Clinical Neurology

Plasma Epidermal Growth Factor Levels Predict Cognitive Decline in Parkinson Disease

Alice S. Chen-Plotkin et al.

ANNALS OF NEUROLOGY (2011)

Add to Collection

Article Multidisciplinary Sciences

Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery

Larry Gold et al.

PLOS ONE (2010)

Add to Collection

Article Biochemical Research Methods

WGCNA: an R package for weighted correlation network analysis

Peter Langfelder et al.

BMC BIOINFORMATICS (2008)

Add to Collection

Article Mathematical & Computational Biology

Adjusting batch effects in microarray expression data using empirical Bayes methods

W. Evan Johnson et al.

BIOSTATISTICS (2007)

Add to Collection

Article Biochemical Research Methods

Proteome analysis of human substantia nigra in Parkinson's disease

M Basso et al.

PROTEOMICS (2004)

Add to Collection

Article Clinical Neurology

The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service

AJ Hughes et al.

BRAIN (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.